bioRxiv Science⌕ Search

Biology subjects

Ellenberg, P.

Publications and source records attributed to Ellenberg, P..

2 recordsLinked to original sources

APOBEC5: characterisation of a novel member of the AID/APOBEC protein family

The AID/APOBEC protein family is involved in diverse biological processes, most notably antiviral innate immunity, a function carried out by APOBEC3 (A3) in placental mammals. A3 is exclusive to this lineage, having emerged after the divergence from marsupials. This raises the question of how marsupials, which lack A3, defend against retroviruses. An uncharacterized A3 homologue, APOBEC5 (A5), is present in marsupial genomes and in some other vertebrate taxa. Here, we use in silico and in vitro approaches to investigate whether A5 serves as a functional antiviral counterpart to A3 in marsupials and whether marsupial genomes contain evidence of past A3-like activity against retroviral infections. We find that A5 was present in the last common ancestor of all jawed vertebrates but has been lost independently in multiple lineages. A5 exhibits unique structural and post-translational features not observed in APOBEC3 or other APOBEC proteins and has a broad subcellular and tissue distribution, suggesting a multifunctional role. Mutagenesis assays demonstrate that A5 functions as a DNA mutator and modestly restricts the infectivity of a model retrovirus, HIV-1, and that this activity is counteracted by the HIV-1 protein, Vif. Furthermore, analysis of the gray short-tailed opossum genome reveals distinct patterns of A3-like restriction in two groups of recently integrated retroviruses, providing direct evidence of an ongoing evolutionary conflict between marsupial APOBEC proteins and retroviruses. This study presents the first characterisation of A5 as a novel AID/APOBEC family member and reveals that marsupials possess an antiviral function homologous to placental A3, shedding light on the evolutionary dynamics of vertebrate antiviral immunity.

evolutionary biology↗

mRNA vaccines encoding membrane-anchored receptor-binding domains of SARS-CoV-2 mutants induce strong humoral responses and can overcome immune imprinting

To address the limitations of whole-spike COVID vaccines, we explored mRNA vaccines encoding membrane-anchored receptor-binding domain (RBD-TMs), each a fusion of a variant RBD, the transmembrane (TM) and cytoplasmic tail (CT) fragments of the SARS-CoV-2 spike protein. In naive mice, RBD-TM mRNA vaccines against ancestral SARS-CoV-2, Beta, Delta, Delta-plus, Kappa, Omicron BA.1 or BA.5, all induced strong humoral responses against the target RBD. Multiplex surrogate viral neutralization (sVNT) assays indicated broad neutralizing activity against a range of variant RBDs. In the setting of a heterologous boost, against the background of exposure to ancestral whole spike vaccines, sVNT studies suggested that RBD-TM vaccines were able to overcome the detrimental effects of immune imprinting. Omicron BA.1 and BA.5 RBD-TM booster vaccines induced serum antibodies with 12 and 22-fold higher neutralizing activity against the target RBD than their equivalent whole spike variants. Boosting with BA.1 or BA.5 RBD-TM provided good protection against more recent variants including XBB and XBB.1.5. Each RBD-TM mRNA is 28% of the length of its whole-spike equivalent. This advantage will enable tetravalent mRNA vaccines to be developed at well-tolerated doses of formulated mRNA. One Sentence SummarymRNA vaccines encoding membrane-anchored RBDs of SARS-CoV-2 mutants are effective vaccines that can overcome immune imprinting in mice

immunology↗